Alzprotect Announces the Appointment of Professor Christian Bailly to its Board of Directors
Lille, France – December 5th, 2024 – Alzprotect, a pioneering biopharmaceutical company developing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Professor Christian Bailly to its Board of Directors.
Professor Christian Bailly brings to Alzprotect substantial expertise in pharmaceutical research and life sciences, built over more than 30 years of experience. Currently an Associate Professor at the University of Lille and an independent consultant for the pharmaceutical industry, Professor Bailly has also held leadership roles in the pharmaceutical sector, notably as Director of Research and Development at Pierre Fabre Médicament.
Renowned for his skills in drug discovery and fostering collaborations between academia and industry, Professor Bailly has led multiple research centers and overseen innovative programs that have resulted in the development of new therapies. His extensive expertise in chemistry, biology, and pharmacology, combined with his commitment to bridging academic and industrial research, will be invaluable in supporting Alzprotect’s strategy for developing treatments for neurodegenerative diseases.
“We are delighted to welcome Professor Christian Bailly to our Board of Directors,” said Dr. Philippe Verwaerde, President of Alzprotect. “His exceptional career and scientific expertise will strengthen our ability to successfully advance our research projects and achieve our strategic goals, particularly in the development of our drug candidate AZP2006.”
Professor Bailly will contribute to shaping Alzprotect’s scientific and strategic vision, emphasizing innovation and the development of treatments that address the needs of patients suffering from conditions such as progressive supranuclear palsy, Alzheimer’s disease, and Parkinson’s disease.
Comment from Professor Bailly, new member of the Board of Directors: "I am thrilled to join the board of one of France’s most innovative companies in the field of neurodegenerative disease treatment, at a pivotal moment as the company transitions to Phase 2/3 trials and pursues ambitious growth. I look forward to contributing to their R&D activities and to their much-anticipated success in serving patients."